International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1858-1862 www.ijprajournal.com ISSN: 2456-4494

Advancing Excellence through Quality by Design- A Detailed Review

Prajakta.S.Kharde, Gayatri.G.Katare , Pratiksha.N.Kedar , Sayali.S.Khairnar , Guided by-Dr.Someshwar Mankar Sir
Pravara Rural College of Pharmacy

Date of Submission: 15-04-2025 Date of Acceptance: 25-04-2025

ABSTRACT: Quality by Design (QbD) is a comprehensive approach to pharmaceutical development, emphasizing design of products and processes for predefined quality. Future research should focus on addressing the challenges of QbD implementation, such as cultural and organizational changes, requirement for specialized skills, and increased costs. There are certain elements of QbD likewise target product profile,design space, and critical quality attributes.It systematically understands relationships between material attributes, process parameters, and product quality. If we implement QbD practice it improved product quality, reduced variability, and increased efficiency. However, implementing QbD might have some challenges. Implementation of QbD requires a deep understanding of material attributes, process parameters, and product quality.

Keywords: QbD, Product Profile, Critical Quality Attributes, Process Prameters

I. INTRODUCTION

Quality by Design (QbD) is a organized approach to process and product development which ensures that the quality is built into a product from the outset. To achieve the desired quality It should be built in by design, rather than tested into products directly. Initially QbD principles were introduced in the pharmaceutical industry only but at this stage QbD principles are applied across multiple sectors including manufacturing,biologics, validation purpose, software development,healthcare,andengineering.QbD focuses on understanding customer requirements,designing processes to meet these needs, and continuously improving based on data and feedback. By using science, risk management, and statistical analysis, QbD reduces the defects, reduces costs, and enhances efficiency and also it is time saving process.

Defination of QbD according to ICH Q8(R1) Guideline:

"Quality by Design (QbD) is a systematic approach to development that begins with predefined objectives and emphasizes product and process understanding and process control, based on sound science and quality risk management."

Defination of QbD according to FDA PAT Guideline:

"Quality by Design (QbD) is a systematic approach to pharmaceutical development that prioritizes understanding and controlling the product and process to ensure consistent quality by designing it in, rather than testing it in."

Objectives[3]

1.Assist continuous improvement : QbD uplift a culture of continuous improvement, allowing pharmaceutical companies to rectify their products and processes over time.

2.Promote manufacturing efficiency : QbD helps to recognise the most critical process parameters and material attributes, allowing for more efficient manufacturing processes.

3.Enhance regulatory compliance : QbD provides a organized approach to pharmaceutical development, which helps to ensure regulatory compliance and reduces the risk of regulatory issues.

4.Ensure consistent product quality : QbD aims to ensure that pharmaceutical products meet their standard specifications or not.

5.Enhances patient safety : By ensuring consistent product quality and reducing mutability, QbD helps to increase patient safety and reduce the risk of adverse events.

6.Reduction in costs : QbD can help to lower the costs by minimizing waste, reducing rework, and improving manufacturing efficiency.

7.Improve knowledge management : QbD provides a framework for knowledge management,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1858-1862 www.ijprajournal.com ISSN: 2456-4494

allowing pharmaceutical companies to capture, store, and share knowledge across the organization.

Goals[1,2]

1. Achieve consistent product quality
2. Ensure patient safety
3. Reduce variability
4. Improve manufacturing efficiency
5. Enhance regulatory compliance
6. Facilitate continuous improvement
7. Increase process understanding
8. Reduce development time and costs

II. METHODOLOGY

Key Elements of QbD[4,5,6]

1.Target Product Profile (TPP): Defines the desired product characteristics, quality attributes, and performance criteria.

2.Critical Quality Attributes (CQAs): Identifies quality attributes critical to product safety, efficacy, and performance.

3.Design Space: Defines the range of conditions that produce a product with desired CQAs.

4.Control Strategy: Ensures process performance and product quality through planned controls.

5.Risk Assessment and Mitigation: Identifies and mitigates risks associated with the product and process.

6.Continual Improvement: Fosters a culture of continuous improvement through regular review and update of the QbD plan.

7.Process Understanding: Develops a deep understanding of the manufacturing process and its impact on product quality.

8.Data-Driven Decision Making: Uses data and scientific knowledge to inform decision-making throughout the product lifecycle.

Steps Involved in Quality by Design Products[8,9]

1. Development of new molecular entity

Preclinical study
Nonclinical study
Clinical Study
Scale up
Submission for market Approval

2. Manufacturing

Design Space
Process Analytical Technology
Real time Quality Control

3. Control Strategy

Risk based decision
Continuous Improvement
Product performance

Seven steps of quality by design start up plan[9]

1. Hire an independent Quality by design expert.
2.Audit of organization and process with expert conducting analysis.
3. Hold a basic quality by design workshop with all your personal.
4. Review the expert's report and recommendation.
5. Draft an implementation plan, timelines and estimated costs.
6. Assign the resources (or contract out).
7. Retain the independent expert as your "Project Assurance" advisor.

Systemic Approach to Qbd[10,11]

1. DEFINE

Provide an overview of the market and intended customers. In this section, Life Sciences teams must detail both the product and its target audience. An essential aspect of Quality by Design (QbD) is to not only articulate the product and its intended consumers but also to outline the specific measurable objectives for the product. These objectives may include aspects such as market share, lead times, launch timelines, performance metrics, pricing strategies, or customer loyalty. Any information that clarifies the market can be highly valuable here.

2. EXPLORE

Investigate the market and understand customer requirements.

Teams should not only analyze the precise needs of the customer and the advantages of the product but also link those needs to the concrete, measurable results that the product will facilitate. The strategies developed in this phase align the design, process, and control aspects with the customer's demands. This approach guarantees that each feature is beneficial to the customer before the product launches.

3. DESIGN

Develop product features that address those requirements.

After comprehending your customers' needs, your team can start crafting the product to satisfy those requirements—preferably in a way that surpasses your competitors. This is a creative endeavor that promotes open-minded thinking while providing a safety net. In the design phase, QbD includes concepts like benchmarking,

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1858-1862 www.ijprajournal.com ISSN: 2456-4494

evaluating various alternatives, and conducting competitor analysis.

4. DEVELOP

Build the processes needed to create those features.

After designing the product, teams must develop the process for delivering the product. This is where process design comes in—a key step in making sure the manufacturer understands all the variables at play, the best ways to ensure quality, and the importance of measuring process capabilities on a frequent basis. The plan will help to ensure all processes are free from defects or deviations.

5. DELIVER

Recognize and establish necessary process controls.

Quality by Design (QbD) continues even after the product enters production. Successful product delivery involves ongoing improvement and meticulous planning. Therefore, following the creation of the processes outlined previously, teams should also assess process controls. This evaluation will assist them in achieving the objectives set forth in the Quality Target Product Profile (QTPP).

ICH Q8,Q9,Q10 Guidelines: Foundation of Qbd[7,12]

Quality by Design in relation to ICH

- Concepts are in agreement
- Understanding relies on Design Space
- Ensuring process reliability
- Use of Design of Experiments (DOE)
- Management of quality

Critical Element: Design Space

-Interactions among multiple dimensions involve variables (such as characteristics of raw materials) and parameters of the process
- Once the design space receives approval, the requirements for regulatory changes after approval will be less complex
- Regulatory flexibility is granted to function within the design parameters
- Improve process comprehension to facilitate a science-based methodology.
- Combine drug substance and drug product process development at their junction.
- Design drug substance characteristics for compatibility with downstream production processes.

Process Analytical Technology (PAT) is a fundamental component of Quality by Design

- Used during development to enhance understanding of the process.
- Adopted in routine manufacturing to oversee the process, ensure product quality, and minimize release testing requirements.
- PAT assessments can substitute for additional laboratory evaluations.

Benefits Involved in QbD[13]

1)Strengthens the scientific basis for evaluations.
2)Facilitates improved collaboration among review, compliance, and inspection teams.
3)Enhances the quality of information in regulatory filings
4)Promotes greater consistency.
5)Elevates the quality of reviews (by establishing a QMS for CMC).
6)Offers increased flexibility in decision-making processes.
7)Guarantees that decisions are grounded in scientific evidence rather than anecdotal data.
8)Engages multiple disciplines in the decision-making process.
9)Allocates resources to tackle higher-risk areas.

Challenges[14]

1. Cultural obstacles:

- Transition from a prescriptive method
- Increased sharing of scientific knowledge

2. Business obstacles:

- Justification for business initiatives
- Support from management
- Budget constraints across different business units

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1858-1862 www.ijprajournal.com ISSN: 2456-4494

3. Challenges in implementation:

- Cross-functional collaboration
- Familiarity with innovative concepts
- Limitations in workload and available resources

Applications of Qbd[15]



Uses of Design-Based Quality

1. Regarding the chromatographic method

a) In identifying impurities
b) In screening chromatography columns
c) In creating the HPLC method for drug product substance
d) In stability tests
e) In capillary electrophoresis
f) In HPLC

2. For the hyphenated method

a)When developing the LC-MS method

3. In the development of bioanalytical methods

4. In research on dissolution

5. When processing complex spectroscopic data

a)In modified release products
b) In IR spectroscopy
c) In mass spectroscopy
d) For spectroscopic measurement

7. The preparation of nanosuspensions during the tableting procedure

9. When examining APIs and excipients In the field of biopharmaceuticals

III. CONCLUSION

The objective of Quality by Design is to establish a dependable method that can be reliably shown to consistently yield data that meets established criteria when operated within specified limits. Quality by Design (QbD) can be utilized for both the development and assessment of analytical methods. In the course of method development, every potential factor (the inputs) and all critical analytical responses (the outputs) are examined to understand their interrelationships. Important analytical factors are identified in a manner that aligns with the process development approaches outlined in ICH Q8 and Q9. A centralized knowledge repository is essential throughout this process to ensure that crucial information is documented and can be revisited or enhanced in the future, allowing insights gained to be applied not only to the specific method being developed but also to other similar methods used in various products. Such a repository, consistent with the principles described in the draft ICH Q10, will facilitate continuous improvement and management of changes to the method over its entire lifecycle.Each time a method undergoes alteration, a risk assessment must be conducted. If the alteration is deemed to have the potential to shift the method beyond its established design space, a method evaluation and, if necessary, a comparability assessment should be carried out to confirm that the method performance criteria continue to be satisfied.

REFERENCES

[1]. Nadpara NP, Thumar R V, Kalola VN, Patel PB. Review Article Quality By Design (Qbd): A Complete Review. 2012;17(2):20–8

[2]. Chavan SD, Pimpodkar N V, Kadam AS, Gaikwad PS, Pharm PD. Research and Reviews : Journal of Pharmaceutical Quality Assurance Quality by Design. 2015;1(2):18–24

[3]. PDA (2012). Quality by Design: A Holistic Approach to Pharmaceutical Development.

[4]. Q9: Quality Risk Management. ICH Harmonized Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2006.

[5]. Q10: Pharmaceutical Quality System, ICH Tripartite Guidelines. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use, 2007.

[6]. Nasr M, FDAs quality initiatives: An update,

http://www.gmpcompliance.com/daten/download/FDAs_Quality_Initiative.pdf, 2007.

[7]. IBM Business Consulting Services, Transforming industrialization: A new paradigm for pharmaceutical development, www.935.ibm.com/services/us/imc/pdf/ge 510– 3997-transforming-industrialization.pdf, 2006.

[8]. Callis JB, Illman DL, Kowalski BR, Process analytical chemistry. Analytical Chemistry, 59, 1987, 624A–637A.

[9]. Munson J, Gujral B, Stanfield CF, A review of process analytical technology (PAT) in the U.S. pharmaceutical industry. Current Pharmaceutical Analysis, 2, 2006, 405–414.

[10]. FDA (2009). Guidance for Industry: Q8(R2) Pharmaceutical Development.

[11]. ICH (2009). Q8(R2) Pharmaceutical Development.

[12]. Food and Drug Administration, Guidance for industry, Q6A specifications for new drug substances and products: Chemical substances, 1999.

[13]. Rathore AS and Winkle H. Quality by Design for biopharmaceuticals. Nature Biotechnology.2009; 27: 26–34

[14]. Jain S. Quality by Design (QbD): A Comprensive understanding of implementation and challenges in pharmaceutical development. Int J of Pharm Pharma Sciences.2014;6(1): 29-35

[15]. Sinica DP, Gholve SB, Ajgunde RR, Bhusnure OG, Thonte SS. Pelagia Research Library Analytical method development and validation by QbD approach – A review. 2015;6(8):18–24